

REMARKS

Claims 1-32 are pending in the application. Claims 27-32 have been cancelled, and claims 2 and 3 have been amended. The cancellation and amendment are made without prejudice and applicants reserve the right to pursue any cancelled subject matter in a future divisional application. The specification has been amended to correct clerical errors.

Specification

The specification has been amended to correct the numbering of the examples in Table 6. The examples in Table 6 follow example 52 and therefore the numbering should start at 53, rather than at 45 as originally presented. The amendment is purely clerical and its entry is respectfully requested.

The examiner requires that applicants provide an abstract on a separate sheet as provided by 37 CFR 1.72(b). However, as set forth in MPEP §1893.03(e), "it is improper for the examiner of the U.S. national stage application to require the applicant to provide an abstract commencing on a separate sheet if the abstract does not appear on a separate sheet in the pamphlet;" accordingly, since the instant application is a national stage application, an abstract on a separate page has not been provided herewith. If unpersuaded, the examiner is invited to contact the undersigned attorney for applicants, and the abstract on a separate page will be supplied.

Rejection under 35 U.S.C. §112, first paragraph

Claims 27-32 stand rejected under 35 U.S.C. §112, first paragraph as allegedly failing to comply with the enabling requirement. Without acquiescing to the examiner's allegation, applicants have cancelled claims 27-32 for the sole purpose of advancing prosecution of the instant application. The rejection is now moot and its withdrawal is respectfully requested.


Rejection under 35 U.S.C. §112, second paragraph

Claims 2, 3, 27, 29, 30 and 32 stand rejected under 35 U.S.C. §112, second paragraph as being indefinite. Claim 2 has been amended to particularly point out that the 1,2,5-thiadiazolyl, oxoxazolyl, isothiazolyl and pyrimidinyl groups are values for R⁵ directly and are not substituents for C₁₋₆alkyl; the amendment is supported by the many examples in the specification such as those in Table 6. Claim 3 has been amended to delete the word "group," the presence of which is clearly a

clerical error. The rejection of claims 27, 29, 30 and 32 is now moot in view of their cancellation. The examiner is respectfully requested to withdraw this ground of rejection.

Applicants believe that the above amendment and remarks place the application in condition for allowance. An early favorable action is respectfully requested.

Respectfully submitted,

By 
Mollie M. Yang
Reg. No. 32,718
Attorney for Applicants
Merck & Co., Inc.
P.O. Box 2000
Rahway, NJ 07065-0907
(732) 594-6343

Date: March 6, 2006